Should we suppress the antigenic stimulus in IPSID for lifelong?
Celik
A F
AF
Pamuk
G E
GE
Pamuk
O N
ON
Uzunismail
H
H
Oktay
E
E
Doğusoy
G
G
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007161:Immunoproliferative Small Intestinal Disease / Q000188:drug therapy* / Q000276:immunology*; D011241:Prednisone / Q000008:administration & dosage; D013752:Tetracycline / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013752:Tetracycline; D011241:Prednisone